The dysregulation of the Ras/Raf/MEK/ERK pathway in cutaneous neurofibromas, epidermal nevi, nevus sebaceous, and other RASopathies of the skin provides the scientific rationale behind our goal to use MEK inhibitors to treat cutaneous neurofibromas, epidermal nevi, and nevus sebaceous. MEK acts downstream of Ras serving as a crucial link in the chain of proteins that passes information from a signaling molecule to the cell’s nucleus. By inhibiting the MEK protein component in the Ras/Raf/MEK/ERK pathway, we can restore a means to regulate the uncontrolled cell division leading to cutaneous neurofibromas and birthmarks.

logo 4png.png